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a b s t r a c t
Objectives: Rapid detection of macrolide resistanceeassociated mutations in Mycoplasma pneumoniae is
crucial for effective antimicrobial treatment. We evaluated the Lightmix Mycoplasma macrolide assay for
the detection of point mutations at nucleotide positions 2063 and 2064 in the 23S ribosomal RNA (rRNA)
gene of M. pneumoniae that confer macrolide resistance.
Methods: Samples from 3438 patients with a respiratory tract infection were analysed byM. pneumoniae
real-time PCR, and 208 (6%) of them were tested positive. In this retrospective study, 163 M. pneumoniae
real-time PCRepositive samples were analysed by the Lightmix assay, and results were compared to
targeted 23S rRNA sequencing.
Results: Macrolide-resistant M. pneumoniae were found in 15 (9%) of 163 retrospectively analysed
samples. The Lightmix assay showed a sensitivity of 100% (95% conﬁdence interval, 78.2e100) and a
speciﬁcity of 100% (95% conﬁdence interval, 97.5e100) as the detected M. pneumoniae genotype (148
wild type and 15 nonewild type) was conﬁrmed by 23S rRNA sequencing in all samples.
Conclusions: The Lightmix assay is an easy-to-use and accurate molecular test that allows rapid determi-
nation ofmacrolide resistance inM. pneumoniae.K.Wagner, ClinMicrobiol Infect 2019;25:383.e5e383.e7
© 2018 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Mycoplasma pneumoniae is a common pathogen causing respira-
tory tract infections, particularly in children and young adults [1].
Macrolides are used as empiric ﬁrst-line treatment ofM. pneumoniae
infections. However, their extensive use led to the rapid worldwide
emergence of clinically macrolide-resistant M. pneumoniae strains
[2,3]. Themainmechanism ofmacrolide resistance inM. pneumoniae
is nucleotide substitutions at positionsA2063andA2064 indomainV
of the 23S ribosomal RNA (rRNA) gene (M. pneumoniae numbering;
corresponds to nucleotide positions 2058 and 2059 in Escherichia
coli) [4].
The aim of this study was to evaluate the reliability and accuracy
of the commercially available molecular Lightmix assay to detect
macrolide-resistant M. pneumoniae in respiratory specimens of
patients with pneumonia.
Methods
Clinical specimens and M. pneumoniae real-time PCR
All respiratory specimens (N ¼ 3438) used in this study were
sent to the Institute of Medical Microbiology, University of Zurich,
between January 2014 and December 2017 for the detection of
respiratory bacterial pathogens, including M. pneumoniae, from
secondary or tertiary care facilities, and were recovered from pa-
tients with respiratory tract infection symptoms. Isolation of
chromosomal DNA and M. pneumoniae real-time PCR (RT-PCR)
detection (henceforward termed M. pneumoniae RT-PCR) was per-
formed on all 3438 respiratory specimens as described previously
[5e7].
Lightmix Mycoplasma macrolide assay
Chromosomal DNA of respiratory specimens was stored
at 20C. Before conducting this retrospective study, the DNA
concentration of all M. pneumoniae RT-PCRepositive samples was
determined using the Qubit dsDNA HS kit (Thermo Fischer
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Scientiﬁc, Schlieren, Switzerland). Samples with a DNA concen-
tration of >0.5 ng/mL were analysed by the Lightmix Mycoplasma
macrolide assay (TIBMolbiol, Berlin, Germany) (Supplementary
Fig. S1). The Lightmix assay consists of a RT-PCR amplifying a
117 bp fragment of the 23S rRNA gene and subsequent melting
curve analysis. The assay was performed on a LightCycler 480-II
instrument (Roche, Rotkreuz, Switzerland). A melting temperature
(Tm) greater 66C in the Lightmix assay indicated a wild-type ge-
notype, while a Tm lower than 62C indicated the presence of a
point mutation at position A2063 or 2064 in the ampliﬁed 23S
rRNA gene, rendering the detected M. pneumoniae macrolide
resistant. To verify the genotype detected by the Lightmix assay, all
163 23S rRNA amplicons were sequenced and analysed with
respect to resistance-conferring point mutations.
23S rRNA RT-PCR amplicon sequencing
The 23S rRNA RT-PCR products were cleaned using AmpPure XP
beads (Beckman Coulter, Nyon, Switzerland), and library prepara-
tion was done with the QIAseq FX DNA library preparation kit
(Qiagen, Hilden, Germany) following the producers' recommen-
dations except omitting the fragmentation step. Sequencing library
quality and size distribution was analysed on a fragment analyser
(Advanced Analytical Technologies, Heidelberg, Germany) using
the Fragment Analyzer 474 HS NGS kit. Sequencing libraries were
pooled in equimolar concentrations and paired-end sequenced
(2  150 bp) on an Illumina MiSeq platform (Illumina, San Diego,
CA, USA). Reads of the 23S rRNA gene sequences of the
M. pneumoniae isolates were mapped to the 23S rRNA gene of
M. pneumoniae strain M129 using CLC Genomic Workbench soft-
ware (Qiagen).
Data analysis
A chi-square test of independence was performed to examine
the associations among age, proportion ofM. pneumoniae infections
and macrolide resistance. All statistical data analysis and data
visualization were performed using R software [8].
Ethics statement
This retrospective study was conducted in accordance with the
Declaration of Helsinki and national and institutional standards.
The act on medical research involving human subjects does not
apply to this study. The study was approved by the ethics com-
mittee of the canton of Zurich, Switzerland (Req-2018-00473).
Results
Overall, 208 of the 3438 respiratory specimens were tested pos-
itive byM. pneumoniae RT-PCR. In 45 of 208M. pneumoniaeepositive
samples, chromosomal DNA was degraded as a result of prolonged
freezing (<0.5 ng/mLDNA;n¼ 7), or sampleswere no longer available
for retrospective testing (n ¼ 38) via the Lightmix assay. Of the
remaining 163 samples, 148 (91%) showed a wild-type genotype in
the Lightmix assay, while 15 (9%) displayed a mutation at nucleotide
position A2063 or A2064 in the 23S rRNA gene conferring resistance
to macrolides (Table 1, Supplementary Fig. S1).
Isolates classiﬁed as M. pneumoniae wild type in the Lightmix
assay did not show a mutation in the domain V of the 23S rRNA
gene, as veriﬁed by 23S rRNA gene amplicon sequencing. For all
samples that showed a shifted melting temperature (Tm < 62C;
n ¼ 15) in the Lightmix assay, sequencing conﬁrmed a mutation
either at nucleotide position 2063 or 2064. We found nine A2063G
mutations, ﬁve A2064G mutations and one A2063C mutation
(Table 1). This resulted in a sensitivity of 100% (95% conﬁdence
interval, 78.2e100) and a speciﬁcity of 100% (95% conﬁdence in-
terval, 97.5e100) of the Lightmix assay.
Interestingly, in our study, we found that the median age of
patients with a M. pneumoniae infection was 15 years, while the
median age of patients with macrolide-resistant M. pneumoniae
infections was 47 years (Supplementary Fig. S2). There was a clear
association between the age of patients and M. pneumoniae infec-
tion (c2 (5, n ¼ 3217) ¼ 328.0, p < 0.001) with the highest pro-
portion of M. pneumoniae infections in patients aged 0 to 20 years
(Supplementary Fig. S3(A)). Interestingly, among patients with
M. pneumoniae infections, younger patients showed infections with
macrolide-susceptible M. pneumoniae, but macrolide-resistant
M. pneumoniae infections were more prevalent in patients aged
>31 years (c2 5, n ¼ 211) ¼ 12.1, p < 0.05), with the strongest as-
sociation in patients aged >50 years (Supplementary Fig. S3(B)).
Discussion
In this retrospective study, the Lightmix Mycoplasma macrolide
assay was evaluated on respiratory specimens of pneumonia pa-
tients and showed high speciﬁcity and sensitivity for the detection
of point mutations in the 23S rRNA gene conferring macrolide
resistance in M. pneumoniae.
In this study, a macrolide resistance rate of 9% was found in
M. pneumoniae when analysing samples from patients treated at
hospitals in Zurich, Switzerland. Prevalence of macrolide resistance
inM. pneumoniae differs in Europe and has been previously reported
as being 0 to 3% inGermany, theNetherlands and Switzerland [9e11],
9.8% in France [12] and 26% in Italy [13]. Differences in observed
resistance rates in this studycompared to previous studies conducted
in Switzerland [9] may be due to two main factors. Firstly, the res-
piratory specimens analysed in this study are mainly obtained from
patients treated at secondary or tertiary care facilities. Therefore, the
patientpopulationmaybe selected in termsof progressionof disease,
severity of pneumonia and proportion of persistent or recurrent
M. pneumoniae infections; further, patients are often already
receiving antibiotic therapy when samples are retrieved for diag-
nostic procedures. Secondly, the age distribution of the patient
population is very broad (1 to 98 years old), and therefore resistance
rates may differ from studies that primarily focused on
M. pneumoniae infection and macrolide resistance in children and
young adults [9]. This notion is supported by the fact that we found a
Table 1
Retrospective analysis of respiratory specimens by Lightmix assay and conﬁrmation of detected Mycoplasma pneumoniae genotype by 23S rRNA amplicon sequencing
M. pneumoniae by RT-PCR Genotype not
determined
Retrospective analysis by Lightmix assay Genotype determined by 23S rRNA
sequencing
Negative Positive WT Non-WT WT Non-WT
3230 (94%) 208 (6%) 45 148 (91%) 15 (9%) 148 A2063C (1  ), A2063G (9  ),
A2064G (5  )
rRNA, ribosomal RNA; RT-PCR, real-time PCR; WT, wild type.
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higher proportion ofmacrolide-resistantM. pneumoniae infections in
patients aged>31 years. This indicates thatmacrolide resistancemay
be associated with age and possibly long-term antibiotic consump-
tion, as macrolides are among the most commonly prescribed anti-
biotics in Switzerland [14].
This study has some limitations. It was designed as a single-
centre laboratory-based, retrospective evaluation study with
extracted DNA from clinical respiratory specimens.We found a high
macrolide resistance rate in M. pneumoniae in the investigated
patient population. This would need to be further addressed in
future studies, including patients from primary care facilities. Thus,
continuous surveillance is crucial to monitor macrolide resistance
in M. pneumoniae and to further investigate its epidemiology in
Switzerland.
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